期刊文献+

血清CysC、ApoA1、C1q在糖尿病肾病早期诊断中的应用价值

Application Value of Serum CysC,ApoA1 and C1q in the Early Diagnosis of Diabetic Nephropathy
下载PDF
导出
摘要 目的分析血清半胱氨酸蛋白酶抑制剂C(cysteine proteinase inhibitor C,CysC)、载脂蛋白A1(apoli popro tein A1,ApoA1)与补体组分1q(recombinant complement component 1,C1q)在糖尿病肾病早期诊断中的应用价值。方法回顾性选取2022年1月—2023年11月南方医科大学第五附属医院收治的220例糖尿病患者(糖尿病组)、90例糖尿病肾病患者(糖尿病肾病组)以及同期在本院进行体检的200名健康人(对照组)的临床资料。比较3组血清CysC、ApoA1、C1q水平,通过受试者操作特征(receiver operating characteristic,ROC)曲线分析CysC、ApoA1、C1q单独与联合检测诊断糖尿病肾病的诊断效能。结果糖尿病肾病组CysC、C1q水平明显均高于糖尿病组和对照组,ApoA1水平低于糖尿病组和对照组,差异有统计学意义(P均<0.05)。ROC曲线分析显示,血清CysC、ApoA1、C1q联合诊断的曲线下面积、灵敏度、特异度均高于单一检测。结论血清CysC、ApoA1、C1q联合检测在糖尿病肾病早期诊断中的应用价值较高,诊断效能较好。 Objective To analyze the application value of serum cysteine proteinase inhibitor C(CysC),apolipoprotein A1(ApoA1)and recombinant complement component 1(C1q)in the early diagnosis of diabetic nephropathy.Methods The clinical data of 220 diabetic patients(diabetic group),90 diabetic nephropathy patients(diabetic ne⁃phropathy group)and 200 healthy people(control group)who underwent physical examination in the Fifth Affiliated Hospital of Southern Medical University from January 2022 to November 2023 were retrospectively selected.The lev⁃els of serum CysC,ApoA1 and C1q were compared among the three groups.The diagnostic efficacy of CysC,ApoA1 and C1 q alone and in combination in the diagnosis of diabetic nephropathy was analyzed by receiver operating charac⁃teristic(ROC)curve.Results The levels of CysC and C1q in the diabetic nephropathy group were significantly higher than those in the diabetic group and the control group,and the level of ApoA1 was lower than that in the diabetic group and the control group,and the differences were statistically significant(all P<0.05).ROC curve analysis showed that the areas under curve,sensitivity and specificity of combined diagnosis of serum CysC,ApoA1 and C1q were higher than those of single detection.Conclusion The application value of serum CysC,ApoA1 and C1q combination detection in the early diagnosis of diabetic nephropathy is high,and the diagnostic efficiency is good.
作者 张桂萍 孙乐栋 张瑞生 张锦欣 叶春秀 ZHANG Guiping;SUN Ledong;ZHANG Ruisheng;ZHANG Jinxin;YE Chunxiu(Department of General Medicine,the Fifth Affiliated Hospital of Southern Medical University,Guangzhou 510900,Guangdong,China;Department of Dermatology,the Fifth Affiliated Hospital of Southern Medical University,Guang-zhou 510900,Guangdong,China;Department of Endocrinology,Gaozhou People's Hospital,Gaozhou 525232,Guangdong,China;Department of Endocrinology,Guangming District People's Hospital,Shenzhen 518106,Guang-dong,China;Department of Thoracic and Cardiovascular Surgery,Shenzhen University General Hospital,Shenzhen 518071,Guangdong,China)
出处 《糖尿病新世界》 2024年第16期53-55,59,共4页 Diabetes New World
关键词 半胱氨酸蛋白酶抑制剂C 载脂蛋白A1 补体组分1q 糖尿病肾病 早期诊断 Cysteine proteinase inhibitor C Apolipoprotein A1 Recombinant complement component 1q Diabetic nephropathy Early diagnosis
  • 相关文献

参考文献12

二级参考文献86

  • 1丁珊珊,刘星玥,马浩.晚期糖基化终末产物介导糖尿病慢性并发症的分子机制研究进展[J].江苏医药,2020,0(2):202-206. 被引量:15
  • 2Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012,379(9818):815-822.
  • 3Parving HH, Lewis JB, Ravid M, et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective[J]. Kidney Int, 2006,69(11):2057-2063.
  • 4Liu ZH. Nephrology in China[J]. Nat Rev Nephrol, 2013,9(9):523-528.
  • 5Woodward M, Patel A, Zoungas S, et al. Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial[J]. Diabetes Care, 2011,34(12):2491-2495.
  • 6Zhuo L, Zou G, Li W, et al. Prevalence of diabetic nephropathy complicating non-diabetic renal disease among Chinese patients with type 2 diabetes mellitus[J]. Eur J Med Res, 2013,18:4.
  • 7KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease[J]. Am J Kidney Dis, 2007,49(2 Suppl 2):S12-S154.
  • 8American Diabetes Association. Standards of medical care in diabetes--2014[J]. Diabetes Care, 2014,37(Suppl 1):S14-S80.
  • 9KDOQI. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease[J]. Kidney Int Suppl, 2013,3(1):1-150.
  • 10Pedrinelli R, Dell′Omo G, Penno G, et al. Non-diabetic microalbu-minuria, endothelial dysfunction and cardiovascular disease[J]. Vasc Med, 2001,6(4):257-264.

共引文献699

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部